clinical trials


atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update

November 15th, 2021 - Ryan Allway

Positive topline results from COMP360’s Phase 2b study RL-007 Phase 2a topline data in cognitive impairment associated with schizophrenia expected end of Q4 Continued progress across 11 therapeutic programs, including initiation of Perception’s Phase 2a and DemeRx’s Phase 1/2 trials as well as interim Phase 2a RL-007 readout of first cohort Launch of atai Impact, a […]

Global Wellness Strategies Shanti Therapeutics Updates and Symbol Change to GWS

October 4th, 2021 - Ryan Allway

The Shanti Therapeutics Focus on Chronic Pain Market with Psychedelics   Vancouver, British Columbia–(Newsfile Corp. – October 4, 2021) – Global Wellness Strategies Inc. (CSE: LOAN) (FSE: O3X4) (OTCQB: PNNRF) (formerly Redfund Capital Corp.) (“Global” or the “Company”) changes symbol to GWS and introduces Dr. Sud Agarwal BSc, MB ChB, FANZCA, the Chairman of Cannvalate Pty Ltd. and Shanti Therapeutics. […]

Big Data and AI Can Guide Cannabis Medicine

August 30th, 2021 - Robin Lefferts

In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to become more homogenous and universal, like the pharmaceutical industry. Pharma companies need to advance more cannabis-derived […]

Ketamine One’s KGK Science Acquisition Provides Numerous Benefits

August 19th, 2021 - Ryan Allway

  KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, […]

New CBD Trials Point the Way for Enveric, MagicMed

July 30th, 2021 - Ryan Allway

  As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug applications for cannabinoids, but that could change. After decades of effective prohibition there […]

Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing

July 29th, 2021 - Ryan Allway

Health Canada Dealer’s License to allow the possession, production, and delivery of all controlled natural psychedelic substances   VANCOUVER, BC , July 29, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (“Filament” or the “Company”), a global leader in natural psychedelic drug development, has been granted an amendment to its existing Health Canada Dealer’s License, amplifying the Company’s position at the […]

Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies

June 16th, 2021 - Ryan Allway

TORONTO, June 16, 2021 /CNW/ – Wake Network Inc. (“Wake” or the “Company“), a global leader in psilocybin and medicinal mushroom production and developer of genomics-based integration therapies, is pleased to announce that it has entered into an agreement with Santé Cannabis (“Sante”) for consultation and clinical research services to support Wake clinical trials in Canada. Both parties to […]

RYAH Medtech Expanding Internationally with Flurry of Deals

June 3rd, 2021 - Robin Lefferts

  A sometimes overlooked aspect of the cannabis industry is the global potential for North American companies. To be sure, the United States and Canada represent the largest and most mature legal cannabis markets, and many companies are rightfully focused on them exclusively. But some companies are set up to not only capitalize on these […]

Cybin Looks to Develop the Next Blockbuster Drugs

May 18th, 2021 - Ryan Allway

The pharmaceutical industry has struggled for years to develop effective psychiatric and neurological treatments. For example, many antidepressants and antipsychotics show only marginal efficacy in reducing symptoms compared to placebos over the short-term. The long-term use of many psychiatric drugs is also associated with adverse side-effects. Psychedelics are an exciting development in neuropsychiatry because of […]

Tryp Therapeutics Partners with Clinlogix for Clinical Trial Support

May 10th, 2021 - Ryan Allway

San Diego, California–(Newsfile Corp. – May 10, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO), to support Tryp’s clinical development of its Psilocybin-for-Neuropsychiatric Disorders (PFNTM) program.   Clinlogix […]

Psychedelic Clinical Trials & Who’s Behind Them

February 18th, 2021 - Ryan Allway

The psychedelics industry has experienced unprecedented growth over the past few years, driven by a combination of emerging research, regulatory support and investor interest. With a growing number of organizations in the space, it can be difficult for investors to keep track of what clinical trials are ongoing and what opportunities lie in the horizon. […]

Revive Therapeutics Aims to Bring Psychedelics to Market

February 17th, 2021 - Ryan Allway

The psychedelic drug market is projected to grow at a 16.3% compound annual growth rate to reach nearly $7 billion by 2027, according to Data Bridge Market Research. While there are a growing number of publicly traded companies in the space, the best opportunities have the right combination of experience, intellectual property and clinical trials. […]

Delic Looks to Build a Sprawling ‘Psychedelic Ecosystem’

January 20th, 2021 - Ryan Allway

There have been a number of high profile initial public offerings in the psychedelic space, including COMPASS Pathways’ (NASDAQ: CMPS) $2 billion debut. While there are now more than 30 publicly traded companies in the space, there are thousands more private companies at various stages of funding and development.  Delic Corp. (CSE: DELC) (OTCQB: DELCF) […]

CBD Innovator, HempFusion, Makes Successful Debut on TSX

January 13th, 2021 - Ryan Allway

  HempFusion Wellness Inc. (TSX: CBD-U) shares soared over 65% following their successful debut on the Toronto Stock Exchange (TSX) on Wednesday, January 6, 2021. Cannabidiol, or CBD, has become one of the most popular health and wellness products in the world over the past couple of years. According to Research and Markets, the global […]

Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector

October 22nd, 2020 - Ryan Allway

The COMPASS Pathways Inc. (NASDAQ: CMPS) initial public offering on the NASDAQ has reinvigorated the psychedelics industry over the past couple of weeks. While COMPASS Pathways Inc. is certainly one of the largest companies in the space, there are a handful of other companies, with experienced management teams, that have raised a significant amount of […]

3 Psychedelic Business Models (and What’s Best for Investors)

October 22nd, 2020 - Ryan Allway

The psychedelics industry has captured the interest of pharmaceutical companies seeking safer and more effective products to address unmet medical needs in mental health. While psychedelic molecules have shown promise, pharmaceutical manufacturers are likely to require that the molecules be improved through scientific engineering to meet specific therapeutic goals and reduce toxicities. There are three […]

Cardiol Therarpeutics Receives FDA Approval For Investigational New Drug (IND) Application For Phase II/III COVID-19 Trial

September 25th, 2020 - Ryan Allway

Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (“Cardiol” or the “Company“), a clinical-stage biotechnology company focused […]

Cannabidiol Phase 1 Clinical Trial Launches, Targeting Inflammatory Heart Condition

September 17th, 2020 - Robin Lefferts

Cannabidiol, or CBD, is thought to be beneficial for a wide variety of ailments, ranging from poor sleep to pain to PTSD and beyond. To this point, however, there haven’t been many clinical trials conducted to thoroughly prove or disprove the benefits of CBD. So far, it has been approved by the U.S. Food and […]

Psychedelics, the Next Frontier in Drug Research

March 1st, 2020 - Ryan Allway

A big factor in the recent rise of cannabis legalization is the emergence of legitimate scientific research into the potential health benefits of the plant’s active ingredients, called cannabinoids. Medicines are often derived from naturally occurring compounds, from aspirin to insulin to penicillin. A decent body of research is currently pointing to psilocybin, the psychedelic […]

CFN Media Exclusive Update from FluroTech President and CEO

November 4th, 2019 - Rachelle Gordon

In the burgeoning cannabis industry, testing companies are often considered the gatekeepers to success. Between consumer demand and regulatory obligations, marijuana producers are compelled to provide a full analysis of what they’re putting on the market and accurate results are crucial. FluroTech (TSX-V: TEST) (OTCQB: FLURF) is a Canadian-based provider of cannabis and hemp testing […]

The Cannabis Waste Problem: How Innovation Leads to Opportunity

September 4th, 2019 - Robin Lefferts

One somewhat unforeseen issue that has arisen as a result of the spreading legalization of cannabis is related to waste, in a variety of forms. Growers use the flower of the plant but dispose of significantly more biomass containing stems, trimmed leaves, and sub-optimal flower.  Unfortunately, there are environmental implications surrounding the disposal of high […]

More Companies Lining Up to Get Their Hands on Lexaria’s DehydraTECH™ Platform

August 15th, 2019 - Ash Stringer

When you’ve got something great, it may take a little bit of time for people to learn about it, but once word starts getting around, it can yield a windfall of interest. That’s the case with Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and its DehydraTECH™ technology that enhances qualities and uptake of all sorts […]

XPhyto Therapeutics Debuts on CSE Under Ticker XPHY

August 6th, 2019 - Ryan Allway

  After about two years of building relationships with exceptional partners and positioning itself in Canada and Europe, XPhyto Therapeutics (CSE: XPHY) was ready to become a public company. That happened Tuesday morning, with trading beginning on the Canadian Securities Exchange, checking off one more box on management’s list of accomplishments. Click here to receive […]

First, Last and Always: Cannabis Innovation Never Ends in Israel

July 25th, 2019 - Ash Stringer

When the word “cannabis” is heard, “Israel” probably isn’t one of the first things that jumps to mind. But, for investors it should be. For that matter, so should EuroMed Therapeutics, an upstart heading toward the public domain. Here’s why. Top Notch R&D, Perfect Weather and Locale  First, simply consider the overall startup picture and […]

Synthetic Cannabinoids: The Harbinger of Cannabis Pharmaceuticals

June 27th, 2019 - Ryan Allway

Many people hear the phrase ‘synthetic’ cannabinoids and immediately think of deadly designer drugs that have swept the recreational market. But synthetic cannabinoids refer to any cannabinoids that are created through chemical or biological processes other than the cultivation and extraction of cannabis plants. These processes could help make cannabinoids much cheaper and chemically-precise — […]

DehydraTECH: The Cynosure of Efficient CBD Delivery

June 13th, 2019 - Ash Stringer

Scientists use words like “bioavailability,” “pharmacokinetics” and “targeted” in describing keys to efficiently treating disease and conditions. To the patient, it is just swallowing a pill, but there is years of research that goes into improving drug delivery with the goal of getting the medicine to the right spot as quickly as possible to maximize […]

Northern Lights Organics Advances CBD Hemp Operations

May 9th, 2019 - Ryan Allway

Organic Hemp Farm Provides Detailed Update on Certified Organic CBD Results as Canadian Market Prepares to Expand VANCOUVER, BC / ACCESSWIRE / May 9, 2019 / Weekend Unlimited Inc. (“Weekend” or the “Company”) (CSE: POT – FSE: 0OS1 – OTCQB: WKULF) is pleased to provide an update on the advancement toward full scale production on its […]

Pascal Biosciences Announces Formation of Clinical Advisory Board

May 8th, 2019 - Ryan Allway

Preeminent Neuro-Oncology Experts to Guide PAS-403 Development Efforts VANCOUVER, British Columbia and SEATTLE, May 08, 2019 (GLOBE NEWSWIRE) — Pascal Biosciences Inc. (TSX.V:PAS)(“Pascal” or the “Company”), a drug discovery and development company, today announced it has formed a clinical advisory board (“CAB”) of preeminent neuro-oncology experts to guide its PAS-403 therapeutic program. PAS-403 is Pascal’s clinical […]

Harvest One Executing on Brands and Distribution Strategy

March 27th, 2019 - Ryan Allway

The nature of the compelling stories in the cannabis industry has changed over the last few years. Remember when a late-stage ACMPR applicant was all the rage? Then it was production expansion and funded capacity. Now, all of that potential is turning to the reality of any market – who can sell product and generate […]

Harvest One Completes First Shipment to Shoppers Drug Mart

March 21st, 2019 - Ryan Allway

SatiSilver™ & SatiGreen™ Now Available for Purchase VANCOUVER, March 21, 2019 /PRNewswire/ – Harvest One Cannabis Inc. (“Harvest One” or the “Company”) (TSXV: HVT; OTCQX: HRVOF), through it’s wholly-owned subsidiary United Greeneries Ltd. (“United Greeneries”), today announced that it has completed its first shipment to Shoppers Drug Mart of Satipharm branded cannabis. Satipharm branded cannabis is now available for […]


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading